{
    "organizations": [],
    "uuid": "2783959cdcdfeff49437d13c7925893ec63c74aa",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-tesaro-announces-positive-top-line/brief-tesaro-announces-positive-top-line-results-from-quadra-trial-of-zejula-idUSFWN1S10NH",
    "ord_in_thread": 0,
    "title": "BRIEF-Tesaro Announces Positive Top-Line Results From Quadra Trial Of Zejula",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " TESARO Inc:\n* TESARO ANNOUNCES POSITIVE TOP-LINE RESULTS FROM QUADRA TRIAL OF ZEJULA\n* TESARO - TRIAL RESULTS SUCCESSFULLY ACHIEVED PRE-SPECIFIED PRIMARY ENDPOINT, DEMONSTRATED ZEJULA MONOTHERAPY ACTIVITY IN BIOMARKER SELECTED PATIENT POPULATION\n* TESARO INC - TRIALâ€™S DATA INTENDED TO SUPPORT LABEL EXPANSION WITH BIOMARKER IN TREATMENT SETTING Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-24T19:12:00.000+03:00",
    "crawled": "2018-04-25T14:27:54.003+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "tesaro",
        "inc",
        "tesaro",
        "announces",
        "positive",
        "result",
        "quadra",
        "trial",
        "zejula",
        "tesaro",
        "trial",
        "result",
        "successfully",
        "achieved",
        "primary",
        "endpoint",
        "demonstrated",
        "zejula",
        "monotherapy",
        "activity",
        "biomarker",
        "selected",
        "patient",
        "population",
        "tesaro",
        "inc",
        "trial",
        "data",
        "intended",
        "support",
        "label",
        "expansion",
        "biomarker",
        "treatment",
        "setting",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}